Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLPLDC Vaccine in Resected Melanoma
NCT02301611Phase 2Completed
- Sponsor
- Elios Therapeutics
- Start
- Jan 2015
- Primary completion
- May 2022
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TLPLDC vaccine in melanoma (2 arms), sponsored by Elios Therapeutics. Primary endpoint: Disease Free Survival at 24 months. Started Jan 2015; status: completed.
02
Drugs
TLPLDC vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02301611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02301611.